<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Collection:</title>
  <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46277" />
  <subtitle />
  <id>http://dspace.bsuedu.ru/handle/123456789/46277</id>
  <updated>2026-04-07T14:05:09Z</updated>
  <dc:date>2026-04-07T14:05:09Z</dc:date>
  <entry>
    <title>Critical aspects of the management of stable coronary artery disease in primary care practice or how to increase the efficacy of evidence-based pharmacological therapy?</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46604" />
    <author>
      <name>Zyryanov, S. K.</name>
    </author>
    <author>
      <name>Fitilev, S. B.</name>
    </author>
    <author>
      <name>Vozzhaev, A. V.</name>
    </author>
    <author>
      <name>Shkrebniova, I. I.</name>
    </author>
    <author>
      <name>Klyuev, D. A.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46604</id>
    <updated>2022-05-06T00:08:15Z</updated>
    <published>2020-01-01T00:00:00Z</published>
    <summary type="text">Title: Critical aspects of the management of stable coronary artery disease in primary care practice or how to increase the efficacy of evidence-based pharmacological therapy?
Authors: Zyryanov, S. K.; Fitilev, S. B.; Vozzhaev, A. V.; Shkrebniova, I. I.; Klyuev, D. A.
Abstract: The publication describes a fragment of the pharmacoepidemiologic study conducted to review the quality of management of patients with stable coronary artery disease (SCAD) in primary care over a 12-year period. The aim of the study was to justify the application of standard operating procedures (SOPs). Such determinants of pharmacotherapy as non-pharmacological modification of cardiovascular risk factors (RFs) and medication adherence were analyzed</summary>
    <dc:date>2020-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Review of machine learning technologies and neural networks in drug synergy combination pharmacological research</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46603" />
    <author>
      <name>Ter-Levonian, A. S.</name>
    </author>
    <author>
      <name>Koshechkin, K. A.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46603</id>
    <updated>2022-05-06T00:11:50Z</updated>
    <published>2020-01-01T00:00:00Z</published>
    <summary type="text">Title: Review of machine learning technologies and neural networks in drug synergy combination pharmacological research
Authors: Ter-Levonian, A. S.; Koshechkin, K. A.
Abstract: Using machine learning (in silico) allows predicting how to get the right combination of drugs and skip the experimental steps in a study that take a lot of time and financial expenses. Gradual preparation is needed for the Deep Learning of Drug Synergy, starting from creating a base of drugs, their characteristics and ways of interacting</summary>
    <dc:date>2020-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity-compound RU-1205</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46602" />
    <author>
      <name>Spasov, A. A.</name>
    </author>
    <author>
      <name>Zvartau, E. E.</name>
    </author>
    <author>
      <name>Grechko, O. I.</name>
    </author>
    <author>
      <name>Eliseeva, N. V.</name>
    </author>
    <author>
      <name>Semenova, Yu. V.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46602</id>
    <updated>2022-05-06T00:08:00Z</updated>
    <published>2020-01-01T00:00:00Z</published>
    <summary type="text">Title: Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity-compound RU-1205
Authors: Spasov, A. A.; Zvartau, E. E.; Grechko, O. I.; Eliseeva, N. V.; Semenova, Yu. V.
Abstract: The clinical use of kappa-opioid agonists, despite their lack of significant drug potential, is limited by the development of severe sedation, dysphoria, depression, and anhedonia. To this date, there are kappa-opioid receptor agonists lacking these side effects due to the selective activation of intracellular signal transmission pathways without p38-MAPK-kinase activation</summary>
    <dc:date>2020-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Influence of Diazepino [1,2-a] benzimidazole derivative (DAB-19) on behavioral aspects of animals</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46592" />
    <author>
      <name>Maltsev, D. V.</name>
    </author>
    <author>
      <name>Spasov, A. A.</name>
    </author>
    <author>
      <name>Miroshnikov, M. V.</name>
    </author>
    <author>
      <name>Skripka, M. O.</name>
    </author>
    <author>
      <name>Divaeva, L. N.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46592</id>
    <updated>2022-05-05T00:20:46Z</updated>
    <published>2020-01-01T00:00:00Z</published>
    <summary type="text">Title: Influence of Diazepino [1,2-a] benzimidazole derivative (DAB-19) on behavioral aspects of animals
Authors: Maltsev, D. V.; Spasov, A. A.; Miroshnikov, M. V.; Skripka, M. O.; Divaeva, L. N.
Abstract: In the present study, compound DAB-19 was screened for its influence on animals` behavior patterns, such as aggression, obsessive-compulsive behavior, emotional lability, and unsociability</summary>
    <dc:date>2020-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

